🇺🇸 FDA
Pipeline program

BRII-835 (VIR-2218)

BRII-179-835-001

Phase 2 small_molecule completed

Quick answer

BRII-835 (VIR-2218) for Hepatitis B, Chronic is a Phase 2 program (small_molecule) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).

Program details

Company
Vir Biotechnology
Indication
Hepatitis B, Chronic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials